duvelisib + venetoclax

Duvelisib + venetoclax is an all-oral, investigational combination therapy being evaluated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter syndrome, and peripheral T-cell lymphoma (PTCL)[1][5][3][7][8]. Duvelisib is a small molecule inhibitor of phosphatidylinositol 3-kinase delta and gamma (PI3Kδ/γ)[2][4], which impedes B-cell survival and proliferation by disrupting PI3K signaling. Venetoclax is a small molecule, selective BCL-2 inhibitor that induces apoptosis in cancer cells by mimicking BH3-only proteins and neutralizing BCL-2’s anti-apoptotic function[6][5]. The combination targets distinct pathways involved in cell survival and proliferation, aiming to achieve potent tumor cell apoptosis especially in high-risk and refractory patients. Both drugs are oral agents; venetoclax is FDA-approved for CLL/SLL, acute myeloid leukemia, and duvelisib is FDA-approved for CLL/SLL, but their combination is investigational and not yet FDA-approved as a fixed combination for any indication[3][5][7].